NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Fate Therapeutics, Inc. (FATE) Stock Analysis

Fate Therapeutics, Inc. (FATE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

FATE

$2.07

+$0.01 (+0.49%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FATE with… →

FATE Key Statistics

As of Oct 21, 2026
Trading
Open
$2.06
Previous Close
$2.06
Day's Range
2.05–2.14
52-Week Range
0.95–3.23
Volume
1.21M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.53
Valuation
Market Cap
$248.03M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
38.21
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.05
Financials (FY)
Revenue (FY)
$6.65M−51.24%
Net Income (FY)
−$136.32M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
119.82M
1-Year Return
+35.29%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
1.61M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, FATE closed at $2.07, +35.29% over 1 year.

Fate Therapeutics, Inc. (FATE) has a market capitalization of $248.03M.

In fiscal 2025, FATE reported revenue of $6.65M.

FATE Stock Return by Calendar Year

Fate Therapeutics, Inc. (FATE) 10-year return: what $10,000 became

1 year
$10,000 $13,529
+35.29%
5 years
$10,000 $348
−96.52%
10 years
$10,000 $8,697
−13.03%

If you had invested $10,000 in Fate Therapeutics, Inc. (FATE) 10 years ago, at the close on October 21, 2016, it would have been worth $8,697 at the close on October 21, 2026: −13.03% in total, −1.39% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+111.22%
2025−40.61%
2024−55.88%
2023−62.93%
2022−82.76%
2021−35.65%
2020+364.64%
2019+52.53%
2018+109.98%
2017+143.43%
2016 (partial year)−3.09%

As of October 21, 2026.

FATE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$6.65M−$136.32M−2,051.1%
2024$13.63M−$186.26M−1,366.5%
2023$63.53M−$160.93M−253.3%
2022$96.30M−$281.72M−292.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$6.65M—−$147.70M−$136.32M−2,051.1%
2024$13.63M—−$195.54M−$186.26M−1,366.5%
2023$63.53M—−$190.51M−$160.93M−253.3%
2022$96.30M—−$308.39M−$281.72M−292.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FATE Valuation vs Biotechnology Median

Median of 608 stocks
MetricFATEBiotechnology medianvs median
P/S ratio38.2113.30187% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Fate Therapeutics, Inc. (FATE) at $248.03M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 161 employees.

Over the past 52 weeks the price has ranged from $0.95 to $3.23. The most recent close on file for FATE is $2.07, dated October 21, 2026. That is +$0.01 (+0.49%) against the previous close. The latest close sits 117.89% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $6.65M. Against the prior fiscal year total of $13.63M, that is a change of −51.24%. The same year closed with a net loss of $136.32M. Trailing earnings per share are −1.05.

Across the 4 fiscal years on file, revenue moves from $96.30M in 2022 to $6.65M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 38.21 times revenue. On price-to-sales that is 187.33% above the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Beta against the wider market is reported at 2.53. Annualized volatility over the trailing 10 years is 86.37%. The trailing one-year total return is +35.29%. Measured over 10 years, that is −1.39% a year compounded.

Growth & Income

The record shows no dividend for FATE.

So far in 2026 the total return is +111.22%. The strongest complete calendar year on file is 2020 at +364.64%; the weakest is 2022 at −82.76%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Fate Therapeutics, Inc. (FATE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Fate Therapeutics, Inc. FATE $248.03M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Fate Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Fate Therapeutics, Inc.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

Visit website →